TGFBR3产品信息
别称:TGFBR3,TGF-beta RIII
物种:Human
属性:Protein
标记:Unconjugated
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>90% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
![1.jpg 1.jpg](/SupplyImg1/2024-06-03/6385302143755860813587402.jpg)
TGFBR3分子背景
TGF-beta RIII是一种膜蛋白,通常与其他TGF-β受体超家族成员一起作为共受体发挥作用。外泌链脱落产生可溶性TGFBR3,这可能会抑制TGFB信号传导。在各种癌症中观察到这种受体的表达减少。或者,编码不同异构体的剪接转录变体已被鉴定用于该基因。
![通用.jpg 通用.jpg](/SupplyImg1/2024-06-03/6385302144741455341025581.jpg)
关键字: TGFBR3;TGFBR3蛋白;TGFBR3重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。